Yours is a timely reminder against over-hype, Rnclarke76. Though I notice you've been a great supporter of RAP.
I would've thought, along with the Motley Fool analyst, Claude Walker*, there'd be more reason for concern about over-hype over there in a company without immediate foreseeable revenues and a market capitalization in excess of $200m, than over here at LSH, already with with growing SaaS based revenues, a market cap currently of just $16m, and backed with about $8m in cash.
All these meditechs face commercial risk, Rnclarke76 - ResApp as much (if not more, having evidently only the one specialized string to the bow) as LSH.
